Tempest Therapeutics, Inc.
TPST
$6.87
$0.385.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.65% | 26.28% | 22.63% | 25.18% | 6.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.23% | 60.06% | 28.27% | 5.18% | -15.89% |
| Operating Income | -85.23% | -60.06% | -28.27% | -5.18% | 15.89% |
| Income Before Tax | -84.47% | -55.56% | -26.24% | -3.51% | 17.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.47% | -55.56% | -26.24% | -3.51% | 17.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.47% | -55.56% | -26.24% | -3.51% | 17.74% |
| EBIT | -85.23% | -60.06% | -28.27% | -5.18% | 15.89% |
| EBITDA | -86.69% | -60.73% | -27.62% | -5.77% | 14.78% |
| EPS Basic | 12.31% | 14.88% | 21.04% | 35.92% | 41.97% |
| Normalized Basic EPS | 12.32% | 14.89% | 21.04% | 35.93% | 41.95% |
| EPS Diluted | 12.31% | 14.88% | 21.04% | 35.92% | 41.97% |
| Normalized Diluted EPS | 12.32% | 14.89% | 21.04% | 35.93% | 41.95% |
| Average Basic Shares Outstanding | 110.36% | 82.74% | 59.88% | 61.55% | 41.75% |
| Average Diluted Shares Outstanding | 110.36% | 82.74% | 59.88% | 61.55% | 41.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |